{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:04:44Z","timestamp":1790147084525,"version":"4.0.1"},"reference-count":69,"publisher":"Informa UK Limited","issue":"13","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.1080\/14656566.2026.2720060","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:05:35Z","timestamp":1787313935000},"page":"1433-1446","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Pearls and pitfalls of oral carbapenem\/penem agents: the promise of a new era or the risk of amplified resistance?"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-9765","authenticated-orcid":false,"given":"Muhammed Cihan","family":"I\u015f\u0131k","sequence":"first","affiliation":[{"name":"Hacettepe University","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-9473","authenticated-orcid":false,"given":"Murat","family":"Akova","sequence":"additional","affiliation":[{"name":"Hacettepe University","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01867-1"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01054-w"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_4_6_1","volume-title":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance. Geneva (CH): World Health Organization; 2024. English."},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-11"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-024-00831-1"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-3-9"},{"key":"e_1_3_4_10_1","unstructured":"U.S. Food and Drug Administration. FDA approves first oral carbapenem therapy for complicated urinary tract infections. 2026 [updated 2026 June 17]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-oral-carbapenem-therapy-complicated-urinary-tract-infections"},{"key":"#cr-split#-e_1_3_4_11_1.1","unstructured":"U.S. Food and Drug Administration. FDA approves new treatment for uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibiotic treatment options [updated 2024 Oct 24"},{"key":"#cr-split#-e_1_3_4_11_1.2","unstructured":"cited 2026 Mar 20]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767070-00006"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2614"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01688-1"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp100130b"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02181-18"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02618-18"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.2010"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01158-15"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01451-22"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad099"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro862"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14070648"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00603-19"},{"key":"e_1_3_4_25_1","volume-title":"Label: uTEBZI (tebipenem pivoxil) tablets, for oral use","author":"U.S. Food and Drug Administration","year":"2026","unstructured":"U.S. Food and Drug Administration. Label: uTEBZI (tebipenem pivoxil) tablets, for oral use. FDA; 2026. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-oral-carbapenem-therapy-complicated-urinary-tract-infections"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1369"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.1224"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac738"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1417"},{"key":"e_1_3_4_30_1","first-page":"S26","article-title":"Effect of various degrees of renal impairment (RI) on the pharmacokinetics (PK) of sulopenem after IV and oral administration [Abstract]","volume":"89","author":"Hazra-Raybon A","year":"2011","unstructured":"Hazra-Raybon A, O\u2019Gorman M, Puttagunta S, et al. Effect of various degrees of renal impairment (RI) on the pharmacokinetics (PK) of sulopenem after IV and oral administration [Abstract]. Clin Pharmacol Ther. 2011;89:S26.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_4_31_1","volume-title":"48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA); October 25\u201328, 2008","author":"O\u2019Donnell J","year":"2008","unstructured":"O\u2019Donnell J, Finegan S, Girard D. Pharmacokinetics and pharmacodynamics of sulopenem in preclinical species. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA); October 25\u201328, 2008; (WA), D.C (USA); 2008."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01832-18"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105462"},{"issue":"1","key":"e_1_3_4_34_1","first-page":"S2","article-title":"173. Oral tebipenem pivoxil hydrobromide versus intravenous imipenem-cilastatin in patients with complicated urinary tract infections or acute pyelonephritis: efficacy and safety results from the phase 3 PIVOT-PO study","volume":"13","author":"Hong DK","year":"2026","unstructured":"Hong DK, Ascioglu S, Bhatt N, et al. 173. Oral tebipenem pivoxil hydrobromide versus intravenous imipenem-cilastatin in patients with complicated urinary tract infections or acute pyelonephritis: efficacy and safety results from the phase 3 PIVOT-PO study. Open Forum Infect Dis. 2026;13(Suppl 1):S2.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.10.025"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400414"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.23.434"},{"issue":"1","key":"e_1_3_4_38_1","first-page":"53","article-title":"Evaluation of safety and efficacy of tebipenem pivoxil granules for pediatric in pneumonia, otitis media and sinusitis","volume":"69","author":"Kataoka H","year":"2016","unstructured":"Kataoka H, Kasahara H, Sasagawa Y, et al. Evaluation of safety and efficacy of tebipenem pivoxil granules for pediatric in pneumonia, otitis media and sinusitis. Jpn J Antibiot. 2016;69(1):53\u201376.","journal-title":"Jpn J Antibiot"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac704"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.2471\/B09585"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06735-y"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2025.102712"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52314"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312"},{"key":"e_1_3_4_45_1","volume-title":"Label: oRLYNVAHTM (sulopenem etzadroxil and probenecid) tablets, for oral use","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. Label: oRLYNVAHTM (sulopenem etzadroxil and probenecid) tablets, for oral use. FDA; 2024. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-024-00454-w"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00142-2"},{"key":"e_1_3_4_48_1","volume-title":"Complicated urinary tract infections: developing drugs for treatment: guidance for industry","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration. Complicated urinary tract infections: developing drugs for treatment: guidance for industry. Revision 1 ed. Silver Spring (MD): US Food and Drug Administration; 2018.","edition":"1"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00360-9"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02346-24"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202188"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2016.12.001"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01495-22"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00590-22"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01061-7"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-006-0401-5"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac399"},{"key":"e_1_3_4_58_1","volume-title":"Carbapenem-resistant Enterobacterales, third update\u20133 February 2025","author":"European Centre for Disease Prevention Control","year":"2025","unstructured":"European Centre for Disease Prevention Control. Carbapenem-resistant Enterobacterales, third update\u20133 February 2025. Stockholm (SE): European Centre for Disease Prevention and Control; 2025."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.03.014"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14060525"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq471"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy978"},{"key":"e_1_3_4_63_1","unstructured":"US Food and Drug Administration. Sulopenem etzadroxil and probenecid \u2013 oral products: U.S. Food and Drug Administration. 2024 [updated 25 Oct 2024; cited 2026]. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/sulopenem-etzadroxil-and-probenecid-oral-products"},{"key":"e_1_3_4_64_1","unstructured":"US Food and Drug Administration. Tebipenem pivoxil \u2013 oral products: U.S. Food and Drug Administration. 2026 [updated 2026 June 17; cited 2026]. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/tebipenem-pivoxil-oral-products"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01214-22"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106733"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2025.06.013"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac333"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6506a1"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.13011"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2720060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2720060","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2720060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:49:51Z","timestamp":1790146191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2720060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":69,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1080\/14656566.2026.2720060"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2720060","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}